Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism. by Farge, D. et al.
icine®
ONAL STUDYMed
OBSERVATIFatal Events in Cancer Patients Receiving Anticoagulant
Therapy for Venous Thromboembolism
Dominique Farge, MD, PhD, Javier Trujillo-Santos, MD, Philippe Debourdeau, MD,
Alessandra Bura-Riviere, MD, PhD, Eva Maria Rodriguez-Beltra´n, MD, Jose Antonio Nieto, MD,
Maria L , David Zeltser, MD, Lucia Mazzolai, MD, Adrian Hij, MD,
CI: 10.2–12.5). Of 4125 p
died of recurrent PE and
DVT, 19 (0.5%) died of PE
Editor: Alessandro Durante
Received: March 17, 2015;
From the Assistance Publ
Internal Medicine and Vas
Thrombosis and Cancer, P
Paris, France (DF); Departm
io Santa-Lucı´a, Cartagena,
Clinique Sainte Catherine
Cancer, Avignon, France (P
de Rangueil, Toulouse, Fra
Hospital Ntra, Sra. de So
Internal Medicine, Hospit
(JAN); Consorcio Hospita
(MLP); Department of In
Center, Tel Aviv, Israel (DZ
Universitaire Vaudois, Lau
Hoˆpitaux de Paris, Saint-L
Disease Unit and Groupe F
France (AH); and Servici
Germans Trias i Pujol, Ba
(MM).
Correspondence: Dominiqu
Saint-Louis Hospital,
Diseases and Vascular
bosis and Cancer (w
University, Sorbonne P
Paris, France (e-mail: d
A full list of RIETE invest
Sanofi Spain supported the
and Bayer Pharma AG
Spain, which accounts
RIETE Registry.
The authors have no confli
Copyright # 2015 Wolters
This is an open access ar
Attribution License 4.0, w
reproduction in any mediu
ISSN: 0025-7974
DOI: 10.1097/MD.0000000
Medicine  Volume 94uisa Peris, MD
,and Manuel Monreal, MD
Abstract: In cancer patients treated for venous thromboembolism
(VTE), including deep-vein thrombosis (DVT) and pulmonary embo-
lism (PE), analyzing mortality associated with recurrent VTE or major
bleeding is needed to determine the optimal duration of anticoagulation.
This was a cohort study using the Registro Informatizado de
Enfermedad TromboEmbo´lica (RIETE) Registry database to compare
rates of fatal recurrent PE and fatal bleeding in cancer patients receiving
anticoagulation for VTE.
As of January 2013, 44,794 patients were enrolled in RIETE, of
whom 7911 (18%) had active cancer. During the course of anticoagulant
therapy (mean, 181 210 days), 178 cancer patients (4.3%) developed
recurrent PE (5.5 per 100 patient-years; 95% CI: 4.8–6.4), 194 (4.7%)
had recurrent DVT (6.2 per 100 patient-years; 95% confidence interval
[CI]: 5.3–7.1), and 367 (8.9%) bled (11.3 per 100 patient-years; 95%atients initially presenting with PE, 43 (1.0%)
45 (1.1%) of bleeding; of 3786 patients with
, and 55 (1.3%) of bleeding. During the first 3
.
revised: May 15, 2015; accepted: July 3, 2015.
ique-Hoˆpitaux de Paris, Saint-Louis Hospital,
cular Disease Unit and Groupe Francophone on
aris7 Diderot University, Sorbonne Paris Cite´,
ent of Internal Medicine, Hospital Universitar-
Murcia, Spain (JT-S); Department of Oncology,
, Groupe Francophone on Thrombosis and
D); Department of Vascular Medicine, Hoˆpital
nce (AB-R); Department of Internal Medicine,
nsoles, Avila, Spain (EMR); Department of
al General Virgen de la Luz, Cuenca, Spain
lario Provincial de Castello´n, Castello´n, Spain
ternal Medicine, Tel Aviv Soursky Medical
); Department of Angiology, Centre Hospitalier
sanne, Switzerland (LM); Assistance Publique-
ouis Hospital, Internal Medicine and Vascular
rancophone on Thrombosis and Cancer, Paris,
o de Medicina Interna, Hospital Universitari
dalona, Universidad Cato´lica de Murcia, Spain
e Farge, Assistance Publique-Hoˆpitaux de Paris,
UH 04 Internal Medicine Unit: Autoimmune
Diseases and Groupe Francophone on Throm-
ww.thrombose-cancer.com), Paris 7 Diderot
aris Cite´; 1 avenue Claude-Vellefaux, 75010
ominique.farge-bancel@aphp.fr).
igators is given in the Appendix.
Registry with an unrestricted educational grant,
supported the part of RIETE Registry outside
for 16.7% of the total patients included in the
cts of interest to disclose.
Kluwer Health, Inc. All rights reserved.
ticle distributed under the Creative Commons
hich permits unrestricted use, distribution, and
m, provided the original work is properly cited.
000001235
, Number 32, August 2015and RIETE Investigators
months of anticoagulation, there were 59 (1.4%) fatal PE recurrences
and 77 (1.9%) fatal bleeds. Beyond the third month, there were 3 fatal
PE recurrences and 23 fatal bleeds.
In RIETE cancer patients, the rate of fatal recurrent PE or fatal
bleeding was much higher within the first 3 months of anticoagulation
therapy.
(Medicine 94(32):e1235)
Abbreviations: CFR = case fatality rate, CI = confidence interval,
CrCl = creatinine clearance, DVT = deep-vein thrombosis, IQR =
interquartile range, IU = international units, LMWH = low-
molecular-weight heparin, PE = pulmonary embolism, RIETE =
Registro Informatizado de Enfermedad TromboEmbo´lica, SD =
standard deviation, UFH = unfractionated heparin, VCF = vena
cava filter, VKA = vitamin K antagonists, VTE = venous
thromboembolism.
INTRODUCTION
D espite appropriate anticoagulation, cancer patients withacute venous thromboembolism (VTE), defined as deep-
vein thrombosis (DVT) or pulmonary embolism (PE), are at
increased risk for VTE recurrences and major bleeding com-
pared to noncancer patients.1–5 Based on randomized clinical
trials6–8 and meta-analyses,9 specific guidelines recommend
that cancer patients with VTE receive initial therapy with low-
molecular-weight heparin (LMWH), Fondaparinux or unfrac-
tionated heparin (UFH), followed by ‘‘early maintenance’’ (10
days to 3 months) and ‘‘long-term treatment’’ (beyond 3
months) with LMWH, rather than with vitamin K antagonists
(VKA).10–14 Use of LMWH from 10 days up to 3 months has
been established by 3 randomized clinical trials6–8 with a high
level of evidence, but there is no consensus regarding the
optimal duration or the intensity of anticoagulation beyond 3
months. It is generally accepted that cancer patients should
receive LMWH during at least 3 months for established VTE up
to 6 months since in the largest study in this setting cancer
patients were treated for 6 months.7 In the absence of data, the
decision regarding the termination or continuation of antic-
oagulation beyond the first 3 or 6 months is largely based on
individual evaluation of the benefit-risk ratio, while considering
the risk of VTE recurrences against the risk of major bleeding,
tolerability, patients’ preference and cancer activity.12,13
The mortality associated with recurrent VTE and major
bleeding provides useful information to balance the respective
risks and benefits of anticoagulation, but most clinical trials were
underpowered to assess the respective risk fatal VTE or fatal
bleeding.15 Furthermore, a number of patients are often excluded
from randomized trials of anticoagulant therapy because of
comorbid conditions, disseminated cancer, short-life expectancy,
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or contraindications, and therefore anticoagulation regimens
based on the results from randomized clinical trials might not
be applicable to all patients with active cancer and VTE.
The Registro Informatizado de Enfermedad TromboEm-
bo´lica (RIETE) Registry is an ongoing, international, multi-
center, prospective registry of consecutive patients presenting
with symptomatic, acute VTE. Its methodology has been
described previously.16–18 In the current analysis, we assessed
the influence of initial VTE presentation—defined as DVT
(including those on central venous catheter) or PE—on the
mortality rate due to VTE recurrences and major bleeding
throughout the whole duration of anticoagulant treatment,
which included use of LMWH, UFH, Fondaparinux, or
VKA. We also compared the rate of fatal recurrent PE and
fatal bleeding over time under the various types of anticoagula-
tion throughout follow-up.
METHODS
Consecutive patients with symptomatic acute VTE con-
firmed by objective tests (contrast venography or ultrasonogra-
phy for suspected DVT, pulmonary angiography, lung
scintigraphy, or helical computed tomography scan for sus-
pected PE) were enrolled in RIETE. Patients were excluded if
currently participating in a therapeutic clinical trial with a
blinded therapy. All patients provided written or oral consent
for participation in the registry, in accordance with local ethics
committee requirements. Participating physicians ensured that
eligible patients were consecutively enrolled. Data recorded on
a computer-based case report form at each participating hospital
were submitted to a centralized coordinating center through a
secure website. Data quality was regularly monitored as pre-
viously described.16–18
Study Design and Outcomes
For this analysis, cancer patients with newly diagnosed
cancer (less than 3 months earlier) or with cancer being treated
by either surgery, chemotherapy, radiotherapy, hormonal, sup-
port therapy, or combined treatments, and receiving anticoagu-
lation (LMWH, UFH, thrombolytics, inferior vena cava filter
(VCF), VKA, or Fondaparinux) for acute VTEwere considered.
VTE initial presentation, clinical characteristics, cancer site and
staging, treatment options and outcome during the course of
anticoagulation were compared. Major outcomes were fatal
(recurrent) PE and fatal bleeding. Fatal PE, in the absence of
autopsy, was defined as any death appearing within the first 10
days after PE diagnosis (either the initial PE episode or recur-
rent PE), in the absence of any alternative cause of death. Fatal
bleeding was defined as any death occurring within 10 days of a
major bleeding episode, in the absence of an alternative cause of
death. Secondary outcomes were the development of DVTor PE
recurrences, major bleeding events and all-cause of death.18
Bleeding complications were classified as ‘‘major’’ if they
were overt and required a transfusion of 2 units of blood or
more, or were retroperitoneal, spinal or intracranial, or when
they were fatal.19 Most outcomes were classified as reported by
the clinical centers. However, if staff at the coordinating center
were uncertain how to classify a reported outcome, that event
was reviewed by a central adjudicating committee (less than
10% of events).
Farge et alBaseline Variables
The following parameters were recorded when the quali-
fying episode of VTE was diagnosed: patient’s gender, age, and
2 | www.md-journal.combody weight; presence of coexisting conditions (chronic heart or
lung disease) and additional VTE risk factors including recent
immobilization (defined as nonsurgical patients confined to bed
with bathroom privileges for 4 days in the 2 months before
VTE diagnosis), and surgery (defined as an operation in the 2
months before VTE); recent (<30 days before VTE) major
bleeding; clinical characteristics of the malignancy (cancer site,
staging, cancer duration since diagnosis); and laboratory data on
admission, including serum creatinine levels.
Treatment and Follow-up
Patients were managed according to the local clinical
practice of each participating hospital, that is, there was no
standardization of anticoagulation treatment. The type
(LMWH, UFH, thrombolytics, VCF, VKA, or Fondaparinux),
dose of LMWH and duration for each type of anticoagulation
were recorded up to 10 days (initial treatment), between 10 days
and 3 months (early maintenance), and after 3 months (long-
term therapy). During each visit after onset of VTE, either in or
out the hospital after discharge or in the outpatient clinic, any
signs or symptoms suggesting either VTE recurrences or bleed-
ing complications were noted. Clinically suspected recurrent
DVTor PE was investigated by repeated imaging as appropriate
according to local physician practice.
Statistical Analysis
Categorical variables were reported as percentages and
compared using the Chi-square test (2-sided) and Fisher exact
test as appropriate. Odds ratios and corresponding 95% confi-
dence intervals (CIs) were calculated, and a P-value <0.05 was
considered to be statistically significant. Continuous variables
were compared with a Student t test. Incidence rates were
calculated as cumulative incidence (events/100 patient-years).
The case-fatality rate (CFR) of recurrent PE andmajor bleeding,
defined as the proportion of patients who die as a consequence
of these conditions, was calculated. Statistical analyses were
conducted with SPSS software for Windows release 15.0 (SPSS
Inc., Chicago, Illinois, USA).
RESULTS
From March 2001 up to January 2013, 7911 (18%) out of
the 44,794 patients enrolled in RIETE had active cancer. Of
these, 4125 cancer patients initially presented with PE (with or
without concomitant DVT) and 3786 with DVT alone. Their
clinical characteristics are depicted in Table 1. Mean age and
body weight were higher in cancer patients presenting with PE
than in those with DVT alone, and they more likely had
additional risk factors for VTE, including immobilization >4
days, postoperative status or renal insufficiency, whereas those
with DVT alone had had more frequent previous VTE. Lung
cancer was more frequent in patients treated for initial PE, and
uterine cancer than in those treated for DVT alone. Most cancer
patients (92%) were initially treated with LMWH, but a higher
proportion of those presenting with PE as compared to those
presenting with DVT alone received UFH (Table 2). Thereafter,
58% of cancer patients continued receiving LMWH at least
during the first 3 months and 35% switched to VKA. LMWH
was initially preferred over VKA in patients with disseminated
cancer (62% received LMWH, 33% VKA) or anemia (66% vs.
30%, respectively). The overall duration of anticoagulation was
Medicine  Volume 94, Number 32, August 2015longer in cancer patients initially presenting with PE than in
those with DVT alone (191 242 days vs. 171 201 days), but
mean daily LMWH doses were similar.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Clinical Characteristics and Additional Risk Factors for Venous Thromboembolism (VTE) According to Initial VTE
Presentation in 7911 Cancer Patients Enrolled in RIETE and Treated for VTE
Pulmonary Embolism Deep-Vein Thrombosis P-Value
Patients, N 4125 3786
Clinical characteristics
Gender (male) 2245 (54%) 2057 (54%) 0.93
Mean age (yearsSD) 68 13 67 13 0.001
Mean body weight (kgSD) 72 14 71 14 <0.001
Additional risk factors for VTE
Immobilization 4 days 858 (21%) 705 (19%) 0.02
Postoperative 668 (16%) 540 (14%) 0.02
Estrogen therapy 37 (6.3%) 41 (7.6%) 0.40
None of the above 2634 (64%) 2567 (68%) <0.001
Prior VTE 485 (12%) 504 (13%) 0.04
Underlying diseases
Chronic lung disease 495 (12%) 335 (8.8%) <0.001
Chronic heart failure 224 (5.4%) 143 (3.8%) <0.001
CrCl levels< 30 mL/minute 247 (6.0%) 294 (7.8%) 0.002
Recent major bleeding 125 (3.0%) 117 (3.1%) 0.88
Anemia 2359 (57%) 2450 (65%) <0.001
Cancer characteristics
Site of cancer
Lung 732 (18%) 443 (12%) <0.001
Colorectal 580 (14%) 596 (16%) 0.04
Breast 527 (13%) 441 (12%) 0.13
Prostate 399 (9.7%) 393 (10%) 0.30
Bladder 204 (4.9%) 256 (6.8%) 0.001
Brain 220 (5.3%) 146 (3.9%) 0.002
Pancreas 190 (4.6%) 180 (4.8%) 0.76
Stomach 185 (4.5%) 171 (4.5%) 0.95
Uterus 142 (3.4%) 179 (4.7%) 0.004
Ovary 141 (3.4%) 116 (3.1%) 0.38
Hematologic 220 (5.3%) 297 (7.8%) <0.001
Other 590 (14%) 578 (15%) 0.23
Metastatic status 2279 (55%) 2043 (54%) 0.25
Diagnosis <3 months earlier 1536 (37%) 1326 (35%) 0.04
Anemia was defined according to the OMS definition (lower than 12.0 g/dL in women, lower than 13 g/dL in men). CrCl¼ creatinine clearance
¼
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During the course of anticoagulation, 178 cancer patients
developed PE recurrences (5.5 per 100 patient-years; 95% CI:
4.8–6.4). Of these, 51 occurred within the first 10 days of
anticoagulation (40 under LMWH, 5 under VKA, 6 other), 105
from Days 11 to 90 (78 on LMWH, 22 VKA, 5 other) and 22
after Day 91 (14 on LMWH, 8 VKA) (Figure 1). PE recurrences
most likely occurred in patients initially presenting with PE than
in those with DVT alone (6.4 vs. 4.6 per 100 patient-years;
P¼ 0.03) (Table 3). Forty-eight patients (27%) died within less
than 24 hours after recurrent PE, with minimal time to change
therapy; 62 continued with the same therapy (same drug and
doses), 47 received higher doses, 21 moved to LMWH, and
VCF was placed in 18. Seventy-three patients (41%) died within
the first 2 weeks, of whom 62 (85%) died of the recurrent PE
event. Overall, PE recurrences developed more likely in patients
levels, SD¼ standard deviation, VTE¼ venous thromboembolism, VTEreceiving long-term LMWH than in those on AVK, but this may
be due to the higher proportion of patients with metastatic
cancer receiving LMWH than AVK (Table 4).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.DVT Recurrences
During the course of anticoagulation, 194 patients pre-
sented with recurrent DVT (6.2; 95% CI: 5.3–7.1). Of these, 17
recurrences appeared within the first 10 days of therapy (13 on
LMWH, 3 VKA, 1 UFH), 130 during ‘‘early maintenance’’ (76
on LMWH, 54 VKA) and 47 during ‘‘long-term’’ treatment
beyond 3 months (28 on LMWH, 19 VKA). DVT recurrences
were more likely to appear in cancer patients initially presenting
with DVT (8.2 vs. 4.3 per 100 patient-years; P< 0.001) than in
those with PE. The type and dose of anticoagulation treatment
was not modified in 105 cancer patients treated for VTE
recurrence, 38 received higher doses of whom 2 died of bleed-
ing after increasing heparin doses, 49 were moved to LMWH,
and a VCF was placed in 8 patients.
Major Bleeding
venous thromboembolism.During the overall duration of anticoagulation, 367 cancer
patients presented major bleeding (11.3 per 100 patient-years;
95% CI: 10.2–12.5). Of these, 249 (68%) were receiving
www.md-journal.com | 3
TABLE 2. Treatment Strategies According to Initial VTE Presentation
Pulmonary Embolism Deep-Vein Thrombosis P-Value
Patients, N 4125 3786
Treatment for cancer
Radiotherapy 455 (11%) 385 (10%) 0.21
Chemotherapy 2031 (49%) 1936 (51%) 0.09
Radiotherapy and chemotherapy 275 (6.7%) 217 (5.7%) 0.09
Hormonal 362 (8.8%) 340 (9.0%) 0.75
Other 160 (4.2%) 209 (5.1%) 0.08
No drug therapy 1566 (38%) 1374 (36%) 0.12
Anticoagulant therapy
Mean days (SD) 191 242 171 201 <0.001
Median days (IQR) 129 (159) 115 (122) 0.047
Initial treatment (Day 0 to Day 10)
Low-molecular-weight heparin 3676 (89%) 3582 (95%) <0.001
Mean LMWH doses (IU/kg/day) 179 41 173 42 <0.001
Unfractionated heparin 353 (8.6%) 118 (3.1%) <0.001
Thrombolytics 29 (0.7%) 6 (0.2%) <0.001
Inferior vena cava filter 217 (5.3%) 155 (4.1%) 0.01
Early maintenance (Day 11 to Day 90)
Vitamin K antagonists 1396 (37%) 1197 (34%) 0.004
Low-molecular-weight heparin 2396 (62%) 2356 (65%) 0.008
Mean LMWH doses (IU/kg/day) 176 41 169 43 <0.001
Long-term therapy (beyond 3 months)
Vitamin K antagonists 995 (42%) 873 (39%) 0.02
Low-molecular-weight heparin 1337 (57%) 1340 (60%) 0.051
Mean LMWH doses (IU/kg/day) 145 49 144 47 0.71
ole
Farge et al Medicine  Volume 94, Number 32, August 2015LMWH, 109 (30%) VKA and 9 (2.5%) were on other treatments
IQR¼ interquartile range, IU¼ international units, LMWH¼ low-m
heparin, VTE¼ venous thromboembolism.including UFH. Anticoagulation was discontinued in 237 patients
(65%) (for <5 days in 172, 5 days in 65), 46 (13%) moved to
low-dose LMWH and a VCF was placed in 36 (9.8%). Major
FIGURE 1. Cumulative rate of recurrent pulmonary embolism (PE), rec
first 12 months of anticoagulation, according to initial venous thromb
alone) in 7911 cancer patients enrolled in RIETE and treated for VTE.
4 | www.md-journal.combleeding occurred within the first 10 days of therapy in 126 cancer
cular-weight heparin, SD¼ standard deviation, UFH¼ unfractionatedpatients (75 under LMWH, 48 VKA, 3 other), in 165 during
‘‘early maintenance’’ (119 on LMWH, 40 VKA, 6 other), and in
76 during ‘‘long-term’’ treatment (55 on LMWH, 21 VKA). The
urrent deep-vein thrombosis (DVT) andmajor bleeding within the
oembolism (VTE) presentation (PE, with or without DVT, or DVT
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 3. Clinical Outcome During the Course of Anticoagulant Therapy in 7911 Cancer Patients Reported to RIETE According to
Initial VTE Presentation
Pulmonary Embolism Deep-Vein Thrombosis
Events, N Events per 100 Patient-Years Events, N Events per 100 Patient-Years P-Value
Patients, N 4125 3786
Years of treatment 1691 1492
Major bleeding 199 11.8 (10.2–13.5) 168 11.3 (9.7–13.1) 0.67
PE recurrences 109 6.4 (5.3–7.7) 69 4.6 (3.6–5.8) 0.03
DVT recurrences 72 4.3 (3.4–5.3) 122 8.2 (6.8–9.7) <0.001
VTE recurrences 181 10.7 (9.2–12.4) 191 12.8 (11.1–14.7) 0.08
Overall death 1342 79.4 (75.2–83.7) 1009 67.6 (63.6–71.9) <0.001
Causes of death
Pulmonary embolism 172 10.2 (8.7–11.8) 19 1.3 (0.8–2.0) <0.001
Initial PE 129 7.6 (6.4–9.0) 0 – –
Recurrent PE 43 2.5 (1.9–3.4) 19 1.3 (0.8–2.0) 0.01
Respiratory insufficiency 94 5.6 (4.5–6.8) 44 2.9 (2.2–3.9) <0.001
Sudden, unexpected 13 0.8 (0.4–1.3) 8 0.5 (0.2–1.0) 0.42
Bleeding 45 2.7 (2.0–3.5) 55 3.7 (2.8–4.8) 0.10
Disseminated cancer 724 42.8 (39.8–46.0) 553 37.1 (34.1–40.3) 0.01
Other 294 17.4 (15.5–19.5) 330 22.1 (19.8–24.6) 0.003
ence
Medicine  Volume 94, Number 32, August 2015 Venous Thromboembolism in Cancer Patientsrate of major bleeding was similar in patients initially presenting
with initial PE or DVT alone (Table 3). During the first 3 months
of anticoagulation, the most common sites of major bleeding were
the gastrointestinal (GI) tract (n¼ 137), urinary (n¼ 39), brain
(n¼ 29), hematoma (n¼ 27), menorrhagia (n¼ 14), and retro-
peritoneal (n¼ 11) (Figure 2). After the third month, the most
common sites of major bleeding were the GI tract (n¼ 33), brain
Results expressed as events per 100 patient-years and 95% confid
VTE¼ venous thromboembolism.(n¼ 16), urinary (n¼ 7), and retroperitoneal (n¼ 5). Sixty-five
(18%) of cancer patients with major bleeding died in<24 hours,
130 (35%) within the first 2 weeks. Of these, 104 (80%) died of
FIGURE 2. Cumulative incidence of major bleeding (and sites of bleed
patients enrolled in RIETE and treated for venous thromboembolism
thrombosis (DVT), or DVT alone).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.bleeding and 4 (3.1%) died of recurrent PE (shortly after dis-
continuing anticoagulation). Overall, major bleeding appeared
more likely in patients receiving long-term LMWH than in those
on AVK, but this may be due to the higher proportion of patients
with metastatic cancer receiving LMWH than AVK (Table 4).
Mortality
intervals. DVT¼ deep-vein thrombosis, PE¼ pulmonary embolism,During anticoagulation for VTE, 2351 cancer patients died
(71.5 per 100 patient-years; 95% CI: 68.6–74.5). The most
common causes of death were: disseminated malignancy
ing) within the first 12 months of anticoagulation in 7911 cancer
(VTE) (pulmonary embolism (PE), with or without deep-vein
www.md-journal.com | 5
TABLE 4. Clinical Outcome During the Course of Anticoagulation, According to Initial VTE Presentation, Period of Therapy and
Prescribed Drugs
Pulmonary Embolism Deep-Vein Thrombosis
Events, N
Events per 100
Patient-Years Events, N
Events per 100
Patient-Years P-Value
Initial therapy (D1–10), UFH 353 118
Metastases 177 (50%) 63 (53%) 0.54
Major bleeding 1 11.1 (0.55–54.7) 1 33.1 (1.7–163) 0.88
PE recurrences 4 44.3 (14.1–107) 0 – 0.26
Fatal recurrent PE 3 33.3 (8.5–90.5) 0 – 0.48
Fatal bleeding 1 11.1 (0.55–54.7) 0 – 0.88
All-cause death 39 432 (312–585) 8 265 (123–503) 0.28
Initial therapy (D1–10), LMWH 3676 3582
Metastases 2058 (56%) 1927 (54%) 0.06
Major bleeding 44 45.1 (33.2–60.0) 31 32.2 (22.2–45.1) 0.19
PE recurrences 25 25.6 (16.9–37.3) 15 15.6 (9.0–25.1) 0.17
Fatal recurrent PE 13 13.3 (7.4–22.2) 3 3.1 (0.8–8.5) 0.02
Fatal bleeding 7 7.2 (3.1–14.2) 13 13.5 (7.5–22.5) 0.24
All-cause death 217 222 (194–253) 115 119 (98.9–143) <0.001
Extended therapy (D11–90), LMWH 2356 2396
Metastases 1553 (65%) 1402 (60%) <0.001
Major bleeding 63 14.4 (11.1–18.3) 56 12.6 (9.6–16.3) 0.53
PE recurrences 46 10.5 (7.8–13.9) 32 7.2 (5.0–10.0) 0.13
Fatal recurrent PE 19 4.3 (2.7–6.6) 12 2.7 (1.5–4.6) 0.26
Fatal bleeding 16 3.7 (2.2–5.8) 22 5.0 (3.2–7.4) 0.44
All-cause death 614 140 (129–152) 486 109 (100–119) <0.001
Extended therapy (D11–90), VKA 1197 1396
Metastases 477 (34%) 469 (39%) 0.008
Major bleeding 23 7.9 (5.2–11.7) 17 6.9 (4.1–10.8) 0.77
PE recurrences 13 4.5 (2.5–7.5) 9 3.6 (1.8–6.7) 0.78
Fatal recurrent PE 1 0.3 (0.02–1.7) 1 0.4 (0.02–2.0) 0.80
Fatal bleeding 3 1.0 (0.3–2.8) 7 2.8 (1.2–5.6) 0.23
All-cause death 96 33.1 (27.0–40.3) 93 37.6 (30.5–45.8) 0.43
Long-term therapy (D> 91), LMWH 1340 1337
Metastases 742 (56%) 700 (52%) 0.09
Major bleeding 29 5.6 (3.8–7.9) 26 6.4 (4.3–9.3) 0.71
PE recurrences 8 1.5 (0.7–2.9) 6 1.5 (0.6–3.1) 0.90
Fatal recurrent PE 0 – 1 0.2 (0.01–1.2) 0.37
Fatal bleeding 7 1.3 (0.6–2.7) 3 0.7 (0.2–2.0) 0.58
All-cause death 207 39.9 (24.8–45.6) 171 42.4 (36.3–48.9) 0.62
Long-term therapy (D> 91), VKA 873 995
Metastases 294 (30%) 277 (32%) 0.31
Major bleeding 13 2.1 (1.2–3.5) 6 1.4 (0.6–3.0) 0.62
PE recurrences 5 0.8 (0.3–1.8) 3 0.7 (0.2–2.0) 0.89
Fatal recurrent PE 2 0.3 (0.1–1.1) 0 – 0.80
Fatal bleeding 7 1.1 (0.5–2.2) 4 1.0 (0.3–2.3) 0.90
All-cause death 65 10.4 (8.07–13.15) 47 11.3 (8.37–14.9) 0.74
, UF
Farge et al Medicine  Volume 94, Number 32, August 2015(n¼ 1277), PE (n¼ 191), respiratory insufficiency (n¼ 138, of
whom 48 had lung cancer, 32 chronic lung disease, and 17
chronic heart failure), and bleeding (n¼ 100). Of 191 cancer
patients with fatal PE, 129 died of the initial PE and 62 of
recurrent PE. Among 100 cancer patients with fatal bleeding,
the most common sites of bleeding were the GI tract (n¼ 51),
and the brain (n¼ 19). During the first 3 months of antic-
LMWH¼ low-molecular-weight heparin, PE¼ pulmonary embolismoagulation, 59 fatal PE recurrences and 77 fatal bleeds occurred
(Figure 3). Beyond the third month, there were 3 fatal PE
recurrences and 23 fatal bleeds. During the first 3 months of
6 | www.md-journal.comanticoagulation, the CFR of recurrent PE was 37.8% (95% CI,
30.2–45.9), compared to 13.6% (95% CI, 3.0–44.9) beyond the
third month. The CFR of major bleeding was 26.3% (95% CI,
21.4–31.7) during the first 3 months, and 31.1% (95% CI,
20.8–42.9) beyond this period.
One in every 4 cancer patients dying of recurrent PE (26%)
or bleeding (27%) had no metastases, 1 in every 2 (61% and
H¼ unfractionated heparin, VKA¼ vitamin K antagonists.34%, respectively) were aged <65 years, and 1 in every 10
patients dying of bleeding had a history of recent bleeding
before the index VTE (Table 5). Moreover, patients with
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 3. Cumulative rate of fatal pulmonary embolism (PE) and
fatal bleedingwithin the first 12months of anticoagulation, accord-
ing to initial venous thromboembolism (VTE) presentation, PE with
or without deep-vein thrombosis (DVT), or DVT alone in 7911
cancer patients enrolled in RIETE and treated by anticoagulation.
TABLE 5. Clinical Characteristics and Treatment in Cancer Patients
Fatal Recurrent PE or Fatal Bleeding According to Time of Presen
10 Days
Fatal Recurrent
PE
Fatal
Bleeding
Patients, N 21 24
Clinical characteristics
Gender (males) 14 (67%) 17 (71%)
Age (mean yearsSD) 63 13 71 13
Age< 65 years 10 (48%) 8 (33%)
Initial presentation as PE 17 (81%) 10 (42%)
Immobilization 4 days 5 (24%) 12 (50%)
Recent major bleeding 1 (4.8%) 5 (21%)
CrCl levels< 30 mL/minute 1 (4.8%) 6 (25%)
Platelets< 80,000/mm3 0 3 (13%)
Cancer characteristics
Site of cancer
Lung 2 (9.5%) 4 (17%)
Colorectal 3 (14%) 3 (13%)
Bladder 2 (9.5%) 3 (13%)
Stomach 2 (9.5%) 2 (8.3%)
Uterus 0 0
Hematologic 0 0
Brain 4 (19%) 0
Pancreas 1 (4.8%) 1 (4.2%)
Prostate 0 2 (8.3%)
Ovary 1 (4.8%) 2 (8.3%)
Breast 1 (4.8%) 0
Other 5 (24%) 7 (29%)
Metastases 14 (67%) 20 (83%)
Diagnosis <3 months earlier 9 (43%) 5 (21%)
Anticoagulant therapy
LMWH 16 (76%) 20 (83%)
Mean LMWH dose (IU/kg/day) 160 49 173 47
UFH 3 (14%) 1 (4.2%)
Mean UFH dose (IU/kg/day) 311 15 400
VKA – –
Pulmonary embolism (PE), with or without deep-vein thrombosis (DVT),
units, LMWH¼ low-molecular-weight heparin, PE¼ pulmonary emb
VKA¼ vitamin K antagonists.
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Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.prostate, bladder, stomach, or uterine cancers less likely died of
PE than of bleeding, while those with breast cancer more likely
died of PE than of bleeding. Finally, 21 patients had a sudden,
unexpected death. Unfortunately, no necropsy studies were
performed, and there is no way to know how many of them
(if any) died of PE or bleeding.
DISCUSSION
This prospective multicenter RIETE cohort analysis of
cancer patients treated for acute VTE, obtained from a large
number of consecutive cancer patients treated for VTE, allowed
to analyze a large cohort of cancer patients treated by antic-
oagulation at best according to these guidelines or according to
local practice. In this specific cancer population treated for
VTE, the overall rate of VTE recurrences during anticoagula-
Venous Thromboembolism in Cancer Patientstion was close to the rate of major bleeding (372 events vs. 367
events), but mortality due to recurrent PE was lower than the
mortality due to bleeding (62 vs. 100 deaths, respectively),
Enrolled in RIETE and Treated by Anticoagulation for VTEWith
tation
11–90 Days >90 Days
Fatal Recurrent
PE
Fatal
Bleeding
Fatal Recurrent
PE
Fatal
Bleeding
38 53 3 23
22 (58%) 35 (66%) 2 (67%) 10 (44%)
65 14 67 11 61 14 66 14
17 (45%) 18 (34%) 1 (33%) 8 (35%)
24 (63%) 20 (38%) 2 (67%) 15 (65%)
11 (29%) 17 (32%) 0 8 (35%)
3 (7.9%) 4 (7.5%) 0 1 (4.3%)
3 (7.9%) 10 (19%) 0 2 (8.7%)
0 2 (3.8%) 0 2 (8.7%)
10 (26%) 10 (19%) 1 (33%) 2 (8.7%)
4 (11%) 6 (11%) 0 2 (8.7%)
2 (5.3%) 6 (11%) 0 2 (8.7%)
0 6 (11%) 1 (33%) 3 (13%)
2 (5.3%) 1 (1.9%) 0 5 (22%)
3 (7.9%) 3 (5.7%) 0 1 (4.3%)
0 2 (3.8%) 0 0
2 (5.3%) 2 (3.8%) 0 1 (4.3%)
1 (2.6%) 2 (3.8%) 0 2 (8.7%)
0 1 (1.9%) 1 (33%) 0
3 (7.9%) 0 0 1 (4.3%)
11 (29%) 14 (26%) 0 4 (17%)
30 (79%) 38 (72%) 2 (67%) 15 (65%)
13 (34%) 30 (57%) 2 (67%) 4 (17%)
31 (82%) 38 (72%) 1 (33%) 10 (%)
183 33 140 50 180 153 45
– – – –
– – – –
2 (5.3%) 10 (19%) 2 (67%) 11 (%)
CrCl¼ creatinine clearance, IQ¼ interquartile range, IU¼ international
olism , SD¼ standard deviation, UFH¼ unfractionated heparin,
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particularly after the third month of anticoagulation (3 vs. 23
deaths, respectively).
These results confirm 2 recent studies showing that the
CFR of recurrent VTE and major bleeding were similar during
initial treatment of VTE in cancer patients, but that the CFR of
recurrent VTE decreased after the third month of anticoagula-
tion.15,20 The higher risk of dying from bleeding than from PE
after the first 3 months of anticoagulation suggests that a less
aggressive anticoagulant strategy (or a shorter duration) might
reduce fatal bleeding, but could also in turn increase the
incidence of PE.
We also found that, irrespective of the type of anticoagu-
lant drugs, the risk of dying from recurrence of PE during
anticoagulation treatment, varied according to VTE presen-
tation at baseline. In patients initially presenting with PE, the
risk of fatal recurrent PE during anticoagulation and the risk of
fatal bleeding were similar. The lower risk of dying from
recurrent PE in patients initially presenting with DVT can be
attributed to the fact that DVT patients most likely recurred as
DVT, and no patient with recurrent DVT died of PE. The dose
of anticoagulation treatment did not appear to account for
difference in outcomes between cancer patients presenting with
VTE alone or with PE, and the rate of fatal bleeding was similar
over time. The much lower risk of dying from PE than from
bleeding in patients with DVT has been previously reported also
in the elderly (with or without cancer),21 and in patients with
renal insufficiency.22 Patients with prostate, bladder, stomach,
or uterine cancers were less likely to die from PE than from
bleeding and patients with breast cancer died more of PE than of
bleeding, underlying the need for tailored anticoagulation regi-
men according to the cancer type in the future.
The incidence of 11 VTE recurrences per 100 patient-years
observed in our study is similar to results from the control arms
of randomized clinical trials using VKA after 10 days as
compared to long-term LMWH for 36,8 or 6 months,7 but the
incidence of 11 major bleeding events per 100 patient-years was
over 2-fold higher than reported in these trials.6–8 The higher
incidence of major bleeding in the current analysis reflects
enrollment of consecutive unselected patients, including more
patients with metastatic cancer and patients with multiple risk
factors for bleeding who are often excluded from randomized
trials. The RIETE registry provides data on the treatment and
outcome of VTE in a real-world situation with an unselected
patient population, in contrast to the rigorously controlled
conditions of randomized clinical studies. There was a rela-
tively low rate of VCF insertion, although 10% of the patients
dying of bleeding had a history of recent bleeding before the
index VTE. A recent RIETE study in 371 patients (of whom 60
with cancer) has shown that inferior VCF insertion, as compared
with anticoagulant therapy, in patients with acute symptomatic
VTE and a significant risk of bleeding was associated with a
lower risk of PE-related death, but did not decrease the rate of
major bleeding at 30 days.23
In the literature, no studies have yet assessed the efficacy
and safety of anticoagulant therapy beyond the first 6 months,
but in a recent survey containing 49 questions on different
aspects of the treatment of cancer patients with VTE, almost
half of the respondents chose to continue LMWH treatment
after the initial 3 to 12 months, most often for life-long.24
According to our findings, indefinite anticoagulation should
probably be reconsidered for some of these patients.
Farge et alThe present study has a number of potential limitations.
First, patients were not treated with a standardized anticoagu-
lant regimen and treatment varied with local practice, which
8 | www.md-journal.comwas influenced by a physician’s assessment of a patient’s risk of
bleeding. Second, data from registries are susceptible to selec-
tion bias if a nonrepresentative sample of patients is selected for
analysis. However, the RIETE registry captured a broad range
of cancer patients with acute symptomatic VTE from multiple
medical centers, countries, and treatment settings, and the study
cohort was less likely a skewed population. Third, to fulfill the
definition of fatal PE in RIETE patients must first experience an
objectively confirmed recurrent PE followed by death within 10
days. Thus, all sudden unexplained deaths, usually considered as
‘‘likely’’ fatal recurrent PE, and many patients dying of respir-
atory insufficiency are not considered in this analysis. Therefore,
the rate of fatal PE may have been underestimated, especially
after hospital discharge. However, over 50% of these patients had
chronic lung or heart disease, or lung cancer, and objective tests
ruled out PE in some of them. Moreover, some deaths occurring at
home without diagnosis may also have been due to cerebral
bleeding. Finally, the study did not use a central committee to
assign cause of death, but the number of deaths in the registry
renders this task virtually impossible. On the other hand, strengths
of the current analysis include that a large number of consecutive
unselected patients were enrolled, and that fatal PE and fatal
bleeding are by far the most important outcomes during the
treatment of acute DVT. When considering the trade-off between
increases in bleeding and decreases in recurrent VTE with
different approaches to management, fatal PE and fatal bleeding
are of equal importance, whereas that is not the case when
nonfatal episodes of recurrent VTE and bleeding are included
(eg, a recurrent DVT and a nonfatal intracranial bleed).
In conclusion, this large prospective RIETE study showed
that the risk of dying from recurrent PE, varied according to VTE
presentation at baseline, irrespective of the type of anticoagula-
tion, and also according to cancer characteristics. In patients
initially presenting with DVT, the risk of dying from recurrent PE
was lower than in those initially presenting with PE. The overall
rate of fatal recurrent PE was close to the rate of fatal bleeding, but
was much higher within the first 3 months of anticoagulation
therapy, suggesting that a less aggressive anticoagulant strategy
(or a shorter duration) might reduce fatal bleeding over time.
Implementation of current guidelines in cancer patients with VTE
Medicine  Volume 94, Number 32, August 2015would benefit from randomized trials, which are needed to
establish whether any different strategy is superior to standard
anticoagulation after 3 months in cancer patients with VTE.
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